Table 4.

Case-control odds ratios for IgE levels by Temodar Use and GBM status, San Francisco Bay Area Adult Glioma Study (2001–2005)

	Controls		All Cases				GBM				Non-GBM
	n	%	n	%	OR* (95% CI)	p- value	n	%	OR* (95% CI)	p- value	n	%	OR* (95% CI)	p- value
All Cases**
Total IgE
			19	5			11	5			8	4
Normal, <25	199	42	7	0	1.00		6	2	1.00		1	8	1.00
			11	2	0.66 (0.48–0.90)			2	0.56 (0.38–0.83)		5	3	0.82 (0.54–1.25)
Borderline, 25 to 100	165	35	1	8		0.01	56	5		0.00	5	3		0.36
				2	0.79 (0.55–1.12)			2	0.81 (0.54–1.23)		3	2	0.70 (0.43–1.16)
Elevated, >100	106	23	85	2		0.18	52	3		0.33	3	0		0.17
No Temodar Use
Total IgE
				4				4			4	4
Normal, <25	199	42	62	6	1.00		21	5	1.00		1	7	1.00
				3	0.77 (0.49–1.22)			3	0.81 (0.39–1.67)		2	3	0.77 (0.45–1.34)
Borderline, 25 to 100	165	35	40	0		0.27	14	0		0.57	6	0		0.36
				2	0.93 (0.57–1.53)			2	1.11 (0.51–2.38)		2	2	0.83 (0.45–1.53)
Elevated, >100	106	23	32	4		0.78	12	6		0.80	0	3		0.55
Used Temodar
Total IgE
			12	5				5			3	4
Normal, <25	199	42	1	4	1.00		88	6	1.00		3	9	1.00
				2	0.57 (0.39–0.83)			2	0.46 (0.30–0.72)		2	3	0.90 (0.50–1.61)
Borderline, 25 to 100	165	35	60	7		0.00	35	2		0.00	5	7		0.72
				1	0.62 (0.40–0.96)			2	0.69 (0.43–1.11)			1	0.45 (0.20–1.00)
Elevated, >100	106	23	43	9		0.03	34	2		0.13	9	3		0.05

^*Models were adjusted for age, gender, ethnicity, college education, and smoking history.

^**Includes cases with unknown Temodar status (35 total).